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Abstract
Variants in the chromosomal region 10q26 are strongly associated with an increased risk for age-related macular
degeneration (AMD). Two potential AMD genes are located in this region: ARMS2 and HTRA1 (high-temperature
requirement A1). Previous studies have suggested that polymorphisms in the promotor region of HTRA1 result in
overexpression of HTRA1 protein. This study investigated the role of HTRA1 overexpression in the pathogenesis of AMD.
Transgenic Htra1 mice overexpressing the murine protein in the retinal pigment epithelium (RPE) layer of the retina were
generated and characterized by transmission electron microscopy, immunofluorescence staining and Western Blot analysis.
The elastic layer of Bruch’s membrane (BM) in the Htra1 transgenic mice was fragmented and less continuous than in wild
type (WT) controls. Recombinant HTRA1 lacking the N-terminal domain cleaved various extracellular matrix (ECM) proteins.
Subsequent Western Blot analysis revealed an overexpression of fibronectin fragments and a reduction of fibulin 5 and
tropoelastin in the RPE/choroid layer in transgenic mice compared to WT. Fibulin 5 is essential for elastogenesis by
promoting elastic fiber assembly and maturation. Taken together, our data implicate that HTRA1 overexpression leads to an
altered elastogenesis in BM through fibulin 5 cleavage. It highlights the importance of ECM related proteins in the
development of AMD and links HTRA1 to other AMD risk genes such as fibulin 5, fibulin 6, ARMS2 and TIMP3.
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Introduction
Age-related macular degeneration (AMD) is the most common
cause of central blindness in the elderly population. Both genetic and
environmental factors play important roles in the development of
AMD. Smoking and dietary intake have been identified as the major
environmental risk factors for developing AMD besides age [1,2]. To
identify genetic risk factors of AMD, genome-wide linkage studies
had been conducted by several groups [3,4,5]. Two major
susceptibility loci were identified: at chromosome 1q31, variants in
the complement factor H (CFH), and variants at chromosome 10q26.
These two loci account for more than 50% of the disease risk [6].
Two potential AMD genes reside in this region: ARMS2 (age-
related maculopathy susceptibility 2) and HTRA1 (high-tempera-
ture requirement factor A1). Ever since, there is considerable
controversy on which gene plays a causal role in AMD [7,8,9,10].
Strong linkage disequilibrium across the region probably makes
genetic studies unsuitable to solve this question. Recently, Tong
et al. (2010) [11] suggested that polymorphisms in both genes were
genetic risk factors of AMD. Polymorphisms in the promotor
region were reported to increase expression levels of HTRA1
[12,13], although others could not confirm these findings [10,14].
HTRA1 is a member of a family of serine proteases characterized
by a highly conserved trypsin-like protease domain and a C-terminal
PDZ domain. A 22 amino acid signal peptide at the N-terminus
markstheHTRA1proteinforsecretion.Itisinvolved indegradation
of extracellular matrix (ECM) proteins like fibronectin [15] and
aggrecan [16]. Elevated HTRA1 levels have been associated with
arthritic disease [15,17,18]. Therefore, it seems to be an important
protein of ECM homeostasis and turnover. Reduced HTRA1
activity didnot represssignaling bythe TGF-ß familyand resulted in
familial ischemic cerebral small-vessel disease [19,20,21]. The
involvement of the ECM in the pathogenesis of AMD is further
supported by additional AMD risk genes such as TIMP3 (tissue
inhibitor of metalloproteinases-3), which inhibits MMPs (matrix
metalloproteinases) and is involved in degradation of the ECM [22],
and ARMS2, which interacts with several ECM proteins [23].
To date, there is no physiological evidence of HTRA1
involvement in AMD pathogenesis. The aim of this study was
the functional analysis of HTRA1 overexpression in the retinal
pigment epithelium (RPE) of the mouse eye. Here, we show for the
first time that an elevated expression of HTRA1 in RPE cells leads
to a change of Bruch’s Membrane (BM) composition in vivo.
Results
Generation of transgenic mice and evaluation of HTRA1
expression
Founder mice were generated by microinjection of the
transgene into the male pronucleus of one-cell embryos, which
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birth to founder mice. The expression of the transgenic construct
was assessed by PCR on genomic DNA. Transgene-specific
primers amplified a transgene cDNA-specific 417-bp sequence in
transgenic, but not in the WT mice (Fig. 1A). Sequencing of the
transgene showed the correct sequence of the complete Rpe65/
Htra1 construct.
To determine the Htra1 mRNA level of transgenic mice
compared to WT, we performed relative quantification by real-
time PCR (Fig. 1B). As a control for experimental variability we
used beta-actin (Actb) as normalizer gene. The fold change in Htra1
gene expression was calculated with the Pfaffl method and
revealed the highest Htra1 gene expression in transgenic line
no. 2 with a 2.79 fold increase compared to WT mice. This is
consistent with findings by Yang et al. [13] who demonstrated a
2.7 fold mRNA increase of HTRA1 in the RPE of patients
genotyped for the risk variant. Therefore, our Htra1 transgenic
mice may be regarded as a physiological model of HTRA1
overexpression and may reflect the situation in AMD patients
carrying the risk variant. Offspring from line no. 2 mice were then
generated by mating a transgenic parent with a C57BL/6N mouse
and expanded by at least six back-crosses. Animals were kept
heterozygous for the transgene.
Since the mRNA levels do not necessarily correlate with protein
levels, we performed Western Blot analysis with RPE/Choroid
lysates of transgenic and WT mice to confirm HTRA1
overexpression on protein level. Here, we found moderate
expression of HTRA1 protein in C57BL/6N mice, while the
Htra1 transgenic mice showed an increase in expression (Fig. 1C).
When we conducted densitometric analysis of our Western Blot
experiments, we detected a 2,68-fold overexpression of HTRA1
protein in the transgenic mice compared to WT mice (Fig. S1).
Thus, mRNA and protein levels of HTRA1 did correlate in our
transgenic mice and both demonstrated a physiological overex-
pression as seen in AMD patients.
To monitor the secretion of HTRA1, we cultured primary RPE
cells from WT and Htra1 transgenic mice and performed Western
Blot analysis of cell culture supernatants (Fig. 1D). Here, we
detected HTRA1 in the supernatant of WT as well as transgenic
mice. This finding clearly demonstrates the secretion of HTRA1
from primary cultured RPE cells into the medium. Note that the
secretion of HTRA1 was increased in Htra1 transgenic mice.
Furthermore, we evaluated HTRA1 expression in other tissues
to demonstrate that the overexpression was restricted to the RPE
due to the Rpe65 Promoter, and that HTRA1 overexpression in
the RPE was not due to any strain variances. Figure 1E illustrates
that no overexpression of HTRA1 protein could be found in brain,
liver, spleen or kidney of transgenic mice when compared to WT
mice.
Morphological evaluation of Htra1 transgenic mice
Morphological screening of WT C57BL/6N and Htra1
transgenic mice up to one year of age via hematoxylin-eosin
(HE) staining on paraffin cross sections revealed no differences in
choroid, BM and RPE (Fig. 2A). In addition, we observed no
differences in vasculature by immunfluorescence for the endothe-
lial cell marker Type-IV collagen (ColIV) (Fig. 2B).
Ultrastructural changes in the elastic layer of Bruch’s
membrane in Htra1 transgenic mice
To further investigate the structural differences, we performed
transmission electron microscopy (TEM). Here, Htra1 transgenic
mice revealed ultrastructural changes in the elastic layer of BM up
to one year of age (Fig. 3 B, D, F and H). The elastic layer of Htra1
Figure 1. Genotyping and protein analysis of Htra1 transgenic
mice. (A) PCR of genomic DNA from transgenic and WT mice.
Transgenic mice show amplification with a visible band at 417 bp (tg)
as can be seen in the positive control (+). WT mice (wt) as well as the
negative control (2) show no amplification. (B) Quantitative real-time
PCR determination of Htra1 mRNA levels from total RNA isolated from
posterior eyes of C57BL/6N and transgenic lines no. 1 to 4 mice. An
increase of Htra1 mRNA in Htra1 transgenic lines compared to WT was
observed. Transgenic line no 2 shows the highest rate with a 2.79 fold
increase (3mice/C57BL/6N and 12mice/transgenic line: 3 independent
experiments, 3mice/group). Data are expressed as means 6SD. Relative
mRNA levels were normalized to Actb and expressed as fold change
relative to control. (C) Western Blot analysis of RPE/Choroid lysates from
3 month old WT (wt) and transgenic (tg) mice. Transgenic mice show a
higher expression of HTRA1 protein compared to WT (1mice/group, 6
independent experiments). Expression of ACTB serves as a loading
control. Image is representative. (D) Western Blot analysis of primary
RPE cells supernatant. Cells were cultured till confluent and medium
was removed 24 hours after exchange of fetal bovine serum-free
medium. The experiment clearly demonstrates secretion of HTRA1 from
RPE cells (1mice/group, 6 independent experiments). Note that the
expression level of HTRA1 is higher in transgenic cell culture
supernatants. Image is representative. (E) Western Blot analysis of
tissue extracts from 3 month old WT (wt) and transgenic mice (tg).
There are no differences in HTRA1 expression found in brain, liver,
spleen and kidney of transgenic mice compared of WT (1mice/group, 6
independent experiments). Expression of ACTB serves as a loading
control. Image is representative.
doi:10.1371/journal.pone.0022959.g001
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material (asterisk Fig. 3 D and H), while the elastic layer of control
mice appeared thick and continuous (Fig. 3 A, C, E, G). To ensure
that the discontinuities are not merely localized irregularities, the
TEM images were made at the central retina as well as the
periphery and graded through blinded and randomized examina-
tion by several independent graders. Fig. S2 indicates the widely
spread morphological changes in the Htra1 transgenic mice
compared to WT.
Expression of ECM proteins in RPE/choroid lysates of WT
and Htra1 transgenic mice
Due to the changes observed in BM of Htra1 transgenic mice in
TEM, we conducted Western Blot analysis of RPE/choroid lysates
to investigate the expression of major components of the ECM as
well as the expression of ECM proteins that are involved in
elastogenesis in Htra1 transgenic compared to WT mice. Figure 4A
clearly demonstrates that the expression of nidogen 1, elastin
microfibril interface-located protein (EMILIN1), fibulin 4 and lysyl
oxidase-like 1 (LOXL1) was comparable in WT and Htra1
transgenic mice. Interestingly, expression levels of fibulin 5, which
has elastogenic activity and tropoelastin were reduced in RPE/
choroid lysates of Htra1 transgenic mice compared to WT.
Densitometric analysis of our Western Blot findings confirmed the
reduction of fibulin 5 and tropoelastin levels (Fig. S3). Western
Blot analysis also revealed higher expression of fibronectin
fragments in transgenic mice (4B). These findings support the
notion of an altered ECM homeostasis in Htra1 transgenic mice.
Distribution of nidogen 1 and nidogen 2 in BM
We performed immunofluorescence staining on paraffin
sections of Htra1 transgenic and WT mice to evaluate the presence
of nidogen 1 and nidogen 2 in BM. Even though we detected
degradation of nidogen 1 and nidogen 2 in our in vitro digestion
assay, we observed no differences in the distribution of nidogen 1
and nidogen 2 in BM of WT and transgenic mice (Fig. 5).
Proteolysis of ECM proteins by HTRA1
To analyze the effects of HTRA1 proteolytic activity on ECM
components of BM, we purified recombinant human His-tagged
Figure 2. Paraffin cross sections of 3 month old WT and Htra1 transgenic mice. (A) HE staining shown in original 406magnification (Scale
Bar: 100 mm). Mice show normal choroidal and retinal architecture (1mice/group, 3 independent experiments). Image is representative. ILM, inner
limiting membrane; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer; PIS, photoreceptor inner
segments; POS, photoreceptor outer segments; RPE, retinal pigment epithelium; BM, Bruch’s membrane. (B) Immunofluorescence for collagen IV (Col
IV) shown in original 1006 magnification (Scale Bar: 100 mm). Transgenic mice show normally developed choroidal vasculature (1mice/group, 3
independent experiments). Image is representative. Green: Collagen IV, Blue: DAPI; RPE, retinal pigment epithelium.
doi:10.1371/journal.pone.0022959.g002
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(Dmac25HTRA1 plasmid kindly provided by Prof. Dr. Ehrmann,
Duisburg-Essen, Germany). To ensure that the bands seen on
Coomassie-stained SDS-Gel for the HTRA1 recombinant protein
were indeed HTRA1 protein, we excised the two bands and
processed them for mass spectrometry. The data showed that the
two bands corresponded to human HTRA1 (Fig. S4). Proteolytic
activity of recombinant HTRA1 was confirmed by ß-casein
digestion (Fig. S5). An Inhibitor of HTRA1 (NVP-LEB748 kindly
provided by Novartis) was used as a control to ensure that
degradation of proteins was specifically due to HTRA1 proteolysis
and not due to any possibly co-purified bacterial proteases. It was
demonstrated to inhibit proteolytic activity by a dose-dependent
manner with an IC50 of 0.21 mm as determined by HTRA1-
dependent digestion of resorufin-labelled casein in an earlier study
by Grau et al. [15].
Figure 3. Transmission electron micrographs of BM. TEM images showing the elastic lamina of BM in WT (A, C, E, G) and Htra1 transgenic (B, D,
F, H) mice (A–D at the age of 3 month; E–H at the age of 12 month). A, B and E, F at original 30006magnification and C, D and G, H at original
200006magnification. Note the fragmentation of the elastic lamina in Htra1 transgenic mice seen as discontinuities in contrast to the continuous
elastic lamina of the WT mice. These discontinuities were observed in all transgenic mice that were analyzed (1mice/group, 6 independent
experiments). Image is representative. BM, Bruch’s membrane; Lv, Lumen vasculare (Lumen of a vessel); Mi, Mitochondria; Pc, Processus cellularis (cell
process); Spi, Spatium intermembranosum (intermembranous cleft).
doi:10.1371/journal.pone.0022959.g003
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to screen for degradation of ECM components. As formerly
described [15], fibronectin is a substrate of HTRA1 and was
degraded after three hours of incubation with recombinant
HTRA1 (Fig. 6A).
Nidogen 1 and nidogen 2, structural constituents of basement
membranes, were also degraded by HTRA1 as shown in Fig. 6B
and 6C. In contrast, laminin and Type-IV collagen showed no
signs of degradation by recombinant HTRA1 in vitro (data not
shown). Note that recombinant HTRA1 also degraded recombi-
nant fibulin 5 (Fig. 6D). When using insoluble elastin from human
skin as a substrate for HTRA1, we failed to observe any
fragmentation bands for elastin (6E). Therefore, HTRA1 seemed
to have no elastase activity.
After 18 hours of incubation and in the absence of substrate a
loss of HTRA1 could be observed in all Figures. This loss was most
likely due to self-degradation of HTRA1 as has been described
before for bacterial HtrA [24] and human HTRA1 [25].
TGF-ß expression in Htra1 transgenic mice
Since HTRA1 is known to inhibit TGF-ß and has an IGF-
binding protein (IGFBP) domain, we were interested in the TGF-ß
and IGF-1 expression in the RPE/choroid layer of Htra1
transgenic mice. We also determined VEGF expression levels
because of its pro-angiogenic properties. To investigate this
expression, we performed Multiplex assays via the Luminex
xMAP Technology (Fig. 7A–C). Transgenic and WT mice showed
no significant differences in the concentration of these growth
factors at young or old age.
Discussion
Polymorphisms in the chromosomal region 10q26 are highly
associated with AMD. Two attractive candidate genes reside in
this region: ARMS2 and HTRA1. There is conflicting data
concerning the involvement of these genes in the pathogenesis of
AMD [9,10,11,12,13]. In this study, we provide the first functional
evidence that HTRA1 overexpression in RPE is involved in AMD
pathogenesis by fragmentation of the elastic layer in BM.
It has long been postulated that BM is important in AMD
development and particularly in formation of choroidal neovas-
cularisation (CNV) in exsudative AMD [26]. Since BM is an
acellular layer, it depends on the adjacent RPE and choroidal cells
Figure 4. Western Blot analysis of RPE/choroid Lysates from
WT (wt) and transgenic (tg) mice. (A) Transgenic mice show a lower
expression of fibulin 5 (FBLN5) and tropoelastin (TE) compared to WT.
Other ECM components like nidogen 1 (NID-1), EMILIN1, fibulin 4
(FBLN4) and LOXL1 are equally expressed (1mice/group, 6 independent
experiments). Expression of ACTB serves as a loading control. Image is
representative. (B) Transgenic mice demonstrate degradation of
f i b r o n e c t i nw i t ht h eg e n e r a t i o nof fibronectin fragments (FN-f)
(1mice/group, 6 independent experiments). Image is representative.
doi:10.1371/journal.pone.0022959.g004
Figure 5. Immunostaining of ECM proteins in BM. (A) Immunofluorescence for nidogen 1 (NID1) and nidogen 2 (NID2) shown in original 406
and 1006magnification (Scale Bar: 100 mm). There is no difference in staining intensity observed between WT and transgenic mice (1mice/group, 3
independent experiments). Image is representative. Green:nidogen 1 and nidogen 2, respectively. BM: Bruch’s membrane; ILM: inner limiting
membrane; RPE: retinal pigment epithelium. Image of H&E stained sections in 406and 1006magnification provides orientation.
doi:10.1371/journal.pone.0022959.g005
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PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e22959Figure 6. Degradation of ECM components by recombinant HTRA1. Purified ECM proteins and purified recombinant HTRA1 were incubated
at 37uC in 50 mM Tris-HCl pH7,6, 5 mM CaCl2, 150 mM NaCl over a period of 18 hours (h). (A) Degradation of fibronectin. Fibronectin (FN) shows no
sign of degradation when incubated alone. Recombinant HTRA1 degrades fibronection after three hours of incubation. The inhibitor of HTRA1
completely abolishes degradation of fibronectin by HTRA1. (B) Degradation of nidogen 1. Nidogen 1 (NID1) shows no sign of degradation when
incubated alone. Recombinant HTRA1 cleaves nidogen-1 after one hours of incubation. The inhibitor of HTRA1 completely abolishes degradation of
nidogen 1 by HtrA1. (C) Degradation of nidogen 2. Nidogen 2 (NID2) shows no sign of degradation when incubated alone. Recombinant HTRA1
cleaves nidogen 2 after one hours of incubation. The inhibitor of HTRA1 completely abolishes degradation of nidogen 2 by HTRA1. (D) Degradation of
fibulin 5 by HTRA1. Fibulin 5 (FBLN5) is degraded by HTRA1 already after one hour, but shows no sign of degradation when incubated alone. The
Overexpression of HTRA1 in Mice
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fibers, thickening and calcifications of BM have been observed
[28]. In this study, transgenic mice overexpressing HTRA1
showed ultrastructural changes of the elastic layer by TEM.
Subsequent Western Blot analysis of major components of the
ECM as well as ECM proteins involved in elastogenesis revealed
an increase in fibronectin fragments and a reduction of fibulin 5
expression in Htra1 transgenic mice compared to WT in RPE/
choroid lysates. In vitro assays showed that HTRA1 degrades
fibulin 5 as well as fibronectin. In addition, it also degraded
nidogen 1 and nidogen 2, which are important structural
constituents of basement membranes. Fibronectin fragments
stimulate the release of cytokines and MMPs from RPE cells
[29] and therefore can alter the homeostasis of the ECM, which
can lead to further degradation of ECM components. Elevated
levels of fibronectin fragments are often found in synovial fluids of
patients with rheumatoid arthrithis [30] and thus are linked to
inflammation. Moreover, intact fibronectin is better able to bind
collagen and mediate its cell binding, thereby stabilizing the ECM.
In contrast, fibronectin fragments have a decreased ability to form
and stabilize the ECM.
While we could observe degradation of nidogen 1 and nidogen
2 in vitro, we failed to observe degradation of nidogen in Htra1
transgenic mice. Our in vitro assays, however, might not reflect
physiological conditions due to the fact that we used recombinant
HTRA1 without the IGFBP/MAC25 homology domain, which
contains an inhibitory element and therefore might have a higher
protease activity than endogenous HTRA1.
Human recombinant HTRA1 failed to cleave insoluble elastin
from human skin, thereby showing that the fragmentation of the
elastic layer in Htra1 transgenic mice is not due to an elastase
activity of HtrA1.
Missense mutations of the fibulin 5 gene have been associated
with AMD [31] and reduced secretion of fibulin 5 has been found
in four AMD mutations [32]. Fibulin 5 is known to be essential for
elastogenesis in vivo as observed with fibulin 5
2/2 mice [33].
Additionally, we were able to demonstrate that transgenic mice
also have lower tropoelastin expression in RPE lysates. Fibulin 5
binds to tropoelastin [34,35] and accelerates self-aggregation of
tropoelastin, a process called coacervation [36]. Together with the
finding of a fragmented elastic lamina in Htra1 transgenic mice,
this result indicates an altered elastic fiber formation due to the
reduction of fibulin 5. Moreover, our in vitro studies demonstrate
that HTRA1 cleaves fibulin 5. In 2007, Hirai et al. [37] reported
that the elastogenic organizer activity of fibulin 5 is abrogated by
proteolytic cleavage, but failed to identify the responsible serine
protease. Here, we report recombinant human HTRA1, a serine
protease to cleave fibulin 5 in vitro. Fibulin 5 promotes elastic fiber
assembly and maturation by organizing tropoelastin, LTBP-2 and
the crosslinking lysyl oxidase-like enzymes LOXL1, 2 and 4 along
Fibrillin microfibrils [38,39,40,41]. Besides, Yu et al. [42]
described fragmentation of the elastic laminar in mice lacking
LOXL1. While we observed a reduction in fibulin 5 and
tropoelastin expression, we didn’t observe changes in the
expression levels of other proteins that take part in elastogenesis.
Therefore, it seems that the reduction of fibulin 5 and neither
fibulin 4, nor EMILIN1, nor LOXL1 impairs elastogenesis in
Htra1 transgenic mice and is responsible for the fragmentation of
the elastic layer in BM as seen in TEM.
This data links HTRA1 into a network of extracellular proteins
involved in AMD (Fig. 8). In addition to fibulin 5, other fibulin
proteins are implicated in macular dystrophies. Recently, it was
shown that ARMS2 interacts with fibulin 6 causing a form of
famililar AMD [23]. Elastic fibers in BM seem to be crucial in the
pathogenesis in AMD. Both fibulins and EMILIN2 (elastin
microfibril interface located protein), another interacting partner
of ARMS2 are involved in elastin biogenesis. The importance of
elastin is further supported by the fact that the concentration of
serum elastin-derived peptides are higher in patients with AMD
than in control subjects [43].
Angiogenesis, a prerequisite of CNV in AMD, is promoted by
both TGF-ß and VEGF. HTRA1 has been demonstrated to
inhibit TGF-ß1 signaling in neuronal cells [44] and is associated
with cerebral autosomal recessive arteriopathy with subcortical
infarcts and leukoencephalopathy (CARASIL) [19]. To test if
HTRA1 inhibition of TGF-ß has any effect on the expression
levels of TGF-ß in Htra1 transgenic mice, we measured expression
levels in a Luminex assay. There was no significant difference in
expression levels for TGF-ß1, 2 and 3 in transgenic compared to
WT mice. Thus, we conclude that the inhibition of TGF-ß by
HTRA1 is negligible in RPE/choroid lysates of Htra1 transgenic
mice.
HTRA1 is also known to have an IGFBP/MAC25 homology
domain and is capable of binding IGF-1. Our results exhibit no
significant changes in IGF-1 and VEGF expression levels in Htra1
transgenic mice and consequently angiogenesis is not differentially
regulated in Htra1 transgenic mice compared to WT mice
regarding these factors.
In summary, our data suggests that an overexpression of
HTRA1 in the RPE leads to an altered BM with fragmentation of
the elastic laminar due to a decrease in fibulin 5, which could be
shown by Western Blot analysis and degradation by recombinant
HTRA1 in vitro. Furthermore, we demonstrate that HTRA1
degrades nidogen 1, nidogen 2 and fibronectin, but not elastin in
vitro. Western Blot analysis also confirmed the degradation of
fibronectin with a higher expression of active fibronectin
fragments in Htra1 transgenic mice. These fragments are known
to have proteolytic activity [45] and stimulate the release of
cytokines and MMPs, which might further contribute to
destabilization of the ECM. This data highlights the importance
of ECM related proteins in the development of AMD. It links
HTRA1 to other AMD risk genes such as fibulin 5, fibulin 6,
ARMS2 and TIMP3.
Materials and Methods
Ethics Statement
This study utilized experiments using mice. All experiments
using mice were performed with consent from the Animal
Experimentation Committee of the University of Cologne
(9.93.2.10.31.07.045). The study did not involve human experi-
ments.
Generation of transgenic mice
A full-length Htra1 cDNA (2030 bp), generated from mouse
cDNA by PCR, was cloned directionally after the murine Rpe65
promoter into a pCI plasmid (Promega) (Fig. 9). The Rpe65
promotor confers tissue specific expression as described by
inhibitor of HTRA1 completely abolishes degradation of fibulin 5 by HTRA1. (E) Degradation of elastin. Elastin (ELN) shows no sign of degradation
when incubated alone and when incubated with recombinant HTRA1.
doi:10.1371/journal.pone.0022959.g006
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further maximize expression. The sequence of the final construct
was confirmed (3123 bp) by DNA sequencing. The construct was
digested with PagI and Bsu15I followed by purification of the 3.9-
kb fragment via agarose gel electrophoresis and millipore
membrane filtration. The linearised transgene was used to
generate seven founder mice via microinjection (ZMMK Service).
The mice were screened for the integrity of the transgene by
sequencing through the entire construct. To expand the transgenic
lines, the founder mice were crossed into a C57BL/6N
background (Charles River Laboratories). All animals investigated
were derived from founder no. 2 and were heterozygous for the
transgene, as they were generated by mating a transgenic parent
with a C57BL/6N mouse.
PCR
Mice were screened for the presence of the transgene by PCR
on genomic DNA. Tail pieces were digested overnight at 56uCi n
lysis buffer (High Pure PCR Template Preparation Kit, Roche),
supplemented with 20 mg/ml proteinase K. DNA was isolated
and quantified according to the manufacturer’s instructions. For
the amplification of the transgene-specific sequence (417 bp) at
56uC, a 59-primer (59- GCAGGCTCCTCCAATAAGG -39) and
a3 9-primer (59- AAGGAAGGAGCCGCTAGCAG -39) were
used to produce a 417 bp product. The amplicons were separated
by agarose gel electrophoresis and detected by ethidium bromide
staining.
Real-time PCR
Total RNA was isolated from RPE/Choroid layers of
transgenic and WT mice, at the age of 3 month, using the
RNeasy Mini Kit (QIAGEN). The cDNA was synthesized with
oligo (dT) Primer using the SuperScript III First-Strand Synthesis
SuperMix (Invitrogen) followed by a RNase H digestion step.
PCR was performed using 12,5 ml of Platinum qPCR Super-
Mix-UGD (Invitrogen), 0,25 ml Universal Probe (Roche), labeled
at the 59 end with fluorescein (FAM) and at the 39 end with a dark
quencher dye, PCR Primers and 5 ml cDNA. Real-time PCR was
performed using the MP 3000 detection system (Stratagene) and
the PCR reaction was carried out at 50uC for 2 minutes and 95uC
for 2 min followed by 50 cycles of 95uC for 15 seconds and 60uC
for 30 seconds. At the end of the PCR cycles, a melting curve,
using a temperature range from 55uCt o9 5 uC with +0.5uC
intervals, was generated to test the specificity of the PCR product.
A cDNA sample in each experiment was tested in triplicate and
each experiment was performed twice. The forward primer for
Htra1 was 59- AGTGGGTCAGGATTCATCGTA -39 and the
reverse primer was 59- GTGACCACGTGAGCATTTGT -39.A s
Figure 7. Luminex Assay of growth factors in RPE/choroid lysates. Concentration of growth factors in RPE/Choroid lysates of transgenic (tg)
and WT (wt) mice at 3 month (young) and 12 month (old) of age (4mice/group, 3independent experiments). Data are presented as means; bars, 6 SD.
(A) Concentration of TGF-ß isoforms in RPE/choroid lysates. WT and transgenic mice show no significant differences in TGF-ß isoform concentration at
young or old age. (B) Concentration of IGF-1 in RPE/choroid lysates. WT and transgenic mice show no significant differences in IGF-1 concentration at
young or old age. (C) Concentration of VEGF in RPE/choroid lysates. WT and transgenic mice show no significant differences in VEGF concentration at
young or old age.
doi:10.1371/journal.pone.0022959.g007
Figure 8. HTRA1 interacts with ECM proteins. Black arrows indicate cleavage by HTRA1. Proteins encoded by genes known to be related to
macular degenerations are circled. Fibulins are delineated by the dashed box. Note that three of five fibulin genes shown have been implicated in
maculopathies, and one of five directly interacts with HTRA1. Reference(s) for interactions described earlier are indicated in small boxes.
[22,23,31,38,47–53] ARMS2, age-related macular susceptibility 2; ELN, elastin; EMILIN, elastin microfibril interface-located protein; FBLN, fibulin; FN,
fibronectin; HTRA1, high-temperature requirement A1; LOXL1, lysyl oxidase-like 1; MMP9, matrix metalloproteinase-9; NID, Nidogen; TIMP3, tissue
inhibitor of metalloproteinase 3.
doi:10.1371/journal.pone.0022959.g008
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No. 88. Actb served as the internal control. The forward primer for
Actb was 59- CCTCACCCTCCCAAAAGC -39 and the reverse
primer was 59- GTGGACTCAGGGCATGGA -39. As Universal
Probe for Actb PCR we selected Universal Probe No. 101. PCR
efficiency represented by a standard curve reached over 95%.
Cell culture
Primary murine RPE cells were isolated from freshly dissected
eyes and cultured in medium Dulbecco’s modified Eagle’s medium
(high glucose, w/glutamine; Gibco Invitrogen) supplemented with
10% fetal bovine serum (PAA), and antibiotics (100 Units/ml
penicillin and 100 mg/ml streptomycin; PAA. Cells were cultured
till confluent and medium was exchanged by fetal serum serum-
free medium 24 hours prior to Western Blot experiments.
Western blot analysis of murine RPE/choroid Lysates
The expression of HTRA1, fibulin 5, fibulin 4, nidogen 1,
EMILIN1, LOXL1 and tropoelastin in the RPE layer of
transgenic and WT mice was evaluated by immunoblotting.
Briefly, the vitreous and retina were removed and RPE/choroid
layers were lysed for 30 min on ice in lysis buffer (RIPA, Bio-Rad
Laboratories) supplemented with a mixture of protease inhibitors
(Bio-Rad Laboratories). The samples were cleared by a centrifu-
gation step (30 min at 10000 g) and the supernatant was assayed
for protein concentration (BCA assay, Thermo Fisher Scientific).
Protein (10 mg) was electrophoresed on AnyKD TGX gel (Bio-
Rad Laboratories). Proteins were electrophoretically transferred to
a PVDF membrane (GE Healthcare) and then blocked in 5% non-
fat milk. After washing blots were probed with antibodies to
HTRA1 (1:1000, rabbit polyclonal, generated from recombinant
HTRA1 lacking the Mac25 homology domain by Pineda), fibulin
5 (1:400, rabbit polyclonal, Santa Cruz Biotechnology), tropoe-
lastin (1:1000, rabbit polyclonal, PR385 Elastin Products Compa-
ny), fibulin 4 (1:1000, rabbit polyclonal, Santa Cruz Biotechnol-
ogy), EMILIN1 (1:1000, rabbit polyclonal, Santa Cruz
Biotechnology), LOXL1 (1:200, rabbit polyclonal, Santa Cruz
Biotechnology), ACTB (1:10000, mouse monoclonal, Abcam).
Polyclonal antibodies against nidogen 1 and fibronectin were
kindly provided by Ursula Hartmann (Ko ¨ln, Germany) and were
used in a 1:1000 dilution. After washing, the respective secondary
peroxidase-labeled antibody (Dako) was applied at a 1:4000
dilution for 1 h at room temperature. Immunoreactive detection
was by chemiluminescence (ECL Plus Western Blotting Chemi-
luminescent Substrate, GE Healthcare). Subsequent densitometric
analysis was performed using the Quantity One Software (Bio-Rad
Laboratories). To account for variations in the applied quantity of
protein, the analysis was made for the signal intensity of HTRA1
as well as for the signal intensity of the loading control. The
relative signal intensity was calculated by dividing the signal
intensity of HTRA1 with the signal intensity of ACTB.
Immunofluorescence
Eyes from 3-month-old C57BL/6N and Htra1 transgenic mice
were enucleated, fixed overnight in methacarn (60% methanol,
30% 1,1,1-trichloroethane and 10% acetic acid), dehydrated and
embedded in paraffin. Sagittal cross-sections were cut at 5 mm,
deparaffinized and hydrated. After treatment for 10 min with
0.005% trypsin at 37uC, sections were blocked for 1 h at room
temperature with 5% BSA and 0.1% Triton X-100 in 0.15 M
NaCl and 50 m M Tris-HCl at pH 7.4 (TBS). They were then
incubated overnight at 4uC with a primary antibody, followed by
1-hour incubation at room temperature with a fluorochrome-
labeled secondary antibody (antirabbit Alexa 488; Invitrogen) in
1:1000 dilution. Slides were examined under a Leica TCS SP5
sectral confocal microscope.
Transmission Electron Microscopy
For morphologic analysis, eyes were removed and then
processed for transmission electron microscopy by conventional
techniques. Tissue was placed in fixative consisting of 2.5%
glutaraldehyde and 2% formaldehyde in 0.1 M cacodylate buffer
and was fixed for 12 to 24 hours at 4uC. The specimens were
subsequently changed to 0.1 M cacodylate buffer for storage at
4uC. The tissue was trimmed to block size and dehydrated in
ethanol prior infiltration with mixtures of propylene oxide and
Epon 812 (Fluka), embedded in pure Epon 812, and polymerized
at 60uC for 18 to 24 hours. One-micrometer sections and thin
sections were cut on an ultramicrotome (Ultracut UCT, Leica).
The 1 mm sections were stained with 0.5% toluidine blue and the
thin sections were stained with saturated aqueous uranyl acetate
and lead stain and then examined under a transmission electron
microscope (EM 902A, Zeiss).
Expression and Purification of HTRA1
The pETDmac25HTRA1 plasmid was kindly provided by
Michael Ehrmann (Essen-Duisburg, Germany). E. coli strain DE3
+
was transformed with the plasmid and grown at 37uC while shaking
till it reached an OD600 of 0.5. Protein expression was induced with
0.5 mM IPTG. After 5 hours at 25uC the cells were centrifuged
(30 min at 4000 g) and the pellet was resuspended in lysis buffer
(500 mM NaH2PO4, 3 M NaCl, pH 7.5) followed by homogeniza-
tion and centrifugation (30 min at 15000 rpm) Precleared cell lysate
was loaded on a Ni
2+-NTA Superflow column (QIAGEN) at a flow
rate of 3 ml/min. The column was washed with wash buffer I
(100 mMTris, 150 mM NaCl, pH 7.5) and buffer II (100 mMTris,
150 mM NaCl, pH 7.5, 5 mM ß-Mercaptoethanol, 30 mM
imidazole) prior to elution in elution buffer (100 mM Tris,
150 mM NaCl, pH 7.5, 5 mM ß-Mercaptoethanol, 150 mM
imidazole). Fractions of 1 ml were collected and analyzed by SDS-
PAGE.ThepurestfractionswerethenloadedtoaHPScolumn(Bio-
Rad Laboratories) at a flow rate of 3 ml/min. The column was
washed with bufferI (50 mMNaCl, 50 mMHEPES/NaOH, adjust
pH to buffer II) and the protein was eluted with buffer II (50 mM
NaCl, 50 mM HEPES/NaOH, 500 mM KH2PO4). Fractions of
4 ml were collected and analyzed by SDS-PAGE. Protein bands
were then cut from the gel and analyzed via peptide mass
fingerprinting (PMF) by the bioanalytic department of the Center
for Molecular Medicine, University of Cologne (CMMC) to confirm
that the purified protein is recombinant HTRA1. Purified protein
was stored in aliquots in storage buffer (50 mM Tris-HCl, 500 mM
NaCl, pH 8.0, 10% glycerol) at 270uC.
Digestion Assays
Degradation of fibronectin (Sigma-Aldrich), fibulin 5 (R&D
Systems), nidogen 1, nidogen 2 (kindly provided by Manuel Koch,
Ko ¨ln, Germany) and insoluble elastin from human skin (Sigma-
Aldrich) was determined by incubation of recombinant HTRA1
with these proteins in 50 mM Tris-HCl, pH 8.5, 150 mM NaCl
for 1, 3 or 18 h at 37uC. ECM proteins and HTRA1 were
incubated separately under the same conditions and served as
Figure 9. Scheme of the transgenic construct Rpe65/Htra1
(3123 bp).
doi:10.1371/journal.pone.0022959.g009
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Novartis) was preincubated with HTRA1 for 20 min at room
temperature at a final concentration of 5 mM prior to the addition
of ECM substrates. Samples were analyzed on a Silver-stained gel.
Luminex Assays
For all Assays, MILLIPLEX Map Kits from Millipore were
used. RPE/Choroid lysates, standards, and quality control
samples (25 ml) were added to a pre-wet filter plate in 96-well
format followed by addition of premixed microspheres. After an
overnight incubation (protected from light; continuous shaking), at
4uC a detection antibodies were added to each well (25 ml) and
were incubated for 1 hour at room temperature. The antigen–
antibody complex was detected by a phycoerythrin-labeled
streptavidin conjugate (25 ml) that was incubated for 30 min at
room temperature. Following a wash step, the signal associated
with each analyte was measured by analyzing the resulting bead-
capture antibody-analyte-detection antibody-Streptavidin-Phyco-
erythrin conjugate complexes on the Luminex 200. The analyte-
specific capture antibodies covalently coupled to spectrally unique
microspheric beads provide analytical specificity. The analyte
concentration is related to the fluorescence intensity derived from
complexed detection conjugates.
Supporting Information
Figure S1 Expression levels of HTRA1 shown by
Western Blot and subsequent densitometric analysis.
(A) Western Blot analysis of RPE/choroid lysates from 3month old
WT (wt) and transgenic (tg) mice. Transgenic mice show a higher
expression of HTRA1 protein compared to WT. Expression of
ACTB serves as a loading control. (B) Densitometric analysis of
HTRA1 expression. The graph demonstrates the relative signal
intensity of WT (wt) and transgenic (tg) mice. Htra1 transgenic mice
show a 2.68 fold increase in signal intensity compared to WT mice.
(TIF)
Figure S2 Transmission electron micrographs of BM.
TEM images showing the elastic lamina of BM in WT (wt) and
Htra1 transgenic (tg) mice at the age of 3 month and at the age of
12 month at original 30006 magnification. Note that the
discontinuities are no local irregularities.
(TIF)
Figure S3 Expression levels of ECM proteins shown by
Western Blot and subsequent densitometric analysis. (A)
Western Blot analysis of RPE/choroid lysates from 3month old
WT (wt) and transgenic (tg) mice. Transgenic mice demonstrate
moderate differences in expression of nidogen 1 (NID1), elastin
microfibril interface-located protein (EMILIN1), fibulin 4 (FBLN4)
and lysyl oxidase-like 1 (LOXL1), protein compared to WT. In
contrast, fibulin 5 (FBLN5) and tropoelastin (TE) show high
reduction of expression levels. Expression of ACTB serves as a
loading control. (B) Densitometric analysis of ECM protein
expression. The graph demonstrates the relative signal intensity
of WT (wt) and transgenic (tg) mice.
(TIF)
Figure S4 Quality control of human recombinant
Dmac25HTRA1. Human recombinant HTRA1 protein showed
two bands when incubated alone and analyzed by SDS-PAGE (left
panel). To ensure the quality of recombinant HTRA1 and rule out
potential contamination with other proteases band (A) and (B)
were excised and analyzed by PMF as described in the method.
Right panel shows the corresponding HTRA1 tryptic peptides
detected in each band.
(TIF)
Figure S5 Degradation of ß-casein by recombinant
HTRA1. Purified ß-casein and purified recombinant HTRA1
were incubated at 37uC in 50 mM Tris-HCl pH7,6, 5 mM
CaCl2, 150 mM NaCl over a period of 3 hours (h). There are no
signs of ß-casein degradation when incubated alone. Recombinant
HTRA1 degrades ß-casein already after 0.5 hours. The inhibitor
of HTRA1 completely abolishes degradation of ß-casein by
HTRA1.
(TIF)
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